Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Wirth

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Gut|February 1, 2020
SUMO pathway inhibition targets an aggressive pancreatic cancer subtypeAlexander Biederstädt, Zonera Hassan, Christian Schneeweis, et al.
JCI Insight|April 19, 2022
Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtypeFelix Orben, Katharina Lankes, Christian Schneeweis, et al.
Blood Advances|August 2, 2022
SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myelomaGuus J J E Heynen, Francis Baumgartner, Michael Heider, et al.
The Journal of Clinical Investigation|May 2, 2022
Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancerUta M Demel, Marlitt Böger, Schayan Yousefian, et al.
Gastroenterology|October 27, 2025
Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancreatic CancerHazal Köse, Christian Schneeweis, Philipp Putze, et al.
Molecular Oncology|September 10, 2024
KRAS<sup>G</sup> <sup>12C</sup>-inhibitor-based combination therapies for pancreatic cancer: insights from drug screeningConstanza Tapia Contreras, Jonas Dominik Falke, Dana-Magdalena Seifert, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 17, 2024
A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis InductionCarolin Schneider, Jorina Hilbert, Franziska Genevaux, et al.
Nature Communications|January 13, 2022
Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphomaMarkus Schick, Le Zhang, Sabine Maurer, et al.
Nature Medicine|September 22, 2015
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinomaPawel K Mazur, Alexander Herner, Stephano S Mello, et al.
Nature Medicine|May 30, 2024
Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinomaPawel K Mazur, Alexander Herner, Stephano S Mello, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Gut|February 1, 2020
SUMO pathway inhibition targets an aggressive pancreatic cancer subtypeAlexander Biederstädt, Zonera Hassan, Christian Schneeweis, et al.
JCI Insight|April 19, 2022
Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtypeFelix Orben, Katharina Lankes, Christian Schneeweis, et al.
Blood Advances|August 2, 2022
SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myelomaGuus J J E Heynen, Francis Baumgartner, Michael Heider, et al.
The Journal of Clinical Investigation|May 2, 2022
Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancerUta M Demel, Marlitt Böger, Schayan Yousefian, et al.
Gastroenterology|October 27, 2025
Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancreatic CancerHazal Köse, Christian Schneeweis, Philipp Putze, et al.
Molecular Oncology|September 10, 2024
KRAS<sup>G</sup> <sup>12C</sup>-inhibitor-based combination therapies for pancreatic cancer: insights from drug screeningConstanza Tapia Contreras, Jonas Dominik Falke, Dana-Magdalena Seifert, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 17, 2024
A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis InductionCarolin Schneider, Jorina Hilbert, Franziska Genevaux, et al.
Nature Communications|January 13, 2022
Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphomaMarkus Schick, Le Zhang, Sabine Maurer, et al.
Nature Medicine|September 22, 2015
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinomaPawel K Mazur, Alexander Herner, Stephano S Mello, et al.
Nature Medicine|May 30, 2024
Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinomaPawel K Mazur, Alexander Herner, Stephano S Mello, et al.
Pageof 7